Adtalem Global Education Inc. (CVSA)
Covista to Report Q4 Earnings: Here's What to Expect This Season
CVSA heads into Q4 earnings with rising enrollment and healthcare education demand expected to support revenue and profit growth.
Covista (CVSA) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Covista (CVSA) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Covista: Not A Clean Story, But The Risk/Reward Has Improved (Rating Upgrade)
Covista demonstrates stabilization, with Q3 FY2026 revenue up 4.5% and positive enrollment trends across key segments. Chamberlain enrollment reached record levels, but revenue growth remains modest; expansion plans could support future growth, though not aggressively priced in. Management raised FY2026 revenue and adjusted EPS guidance, signaling confidence in earnings power despite margin pressures and regulatory risks.
Why Covista (CVSA) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wall Street Analysts Think Covista (CVSA) Could Surge 27.1%: Read This Before Placing a Bet
The mean of analysts' price targets for Covista (CVSA) points to a 27.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Covista (CVSA) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Covista (CVSA) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Covista (CVSA) Upgraded to Buy: Here's Why
Covista (CVSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Covista Q3 Earnings & Revenues Beat Estimates on Enrollment Growth
CVSA surpasses Q3 top and bottom-line estimates as enrollment growth and healthcare demand boosted momentum.
Covista Inc. (CVSA) Q3 2026 Earnings Call Transcript
Covista Inc. (CVSA) Q3 2026 Earnings Call Transcript
Covista (CVSA) Q3 Earnings and Revenues Top Estimates
Covista (CVSA) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $1.92 per share a year ago.
